Peptide dose, affinity, and time of differentiation can contribute to the Th1/Th2 cytokine balance.
Opposing viewpoints exist regarding how Ag dose and affinity modulate Th1/Th2 differentiation, with data suggesting that both high and low level stimulation favors Th2 responses. With transgenic T cells bearing a single TCR, we present novel data, using peptides differing in affinity for the TCR, that show that the time period of differentiation can determine whether Th1 or Th2 responses predominate as the level of initial stimulation is altered. Over the short term, IFN-gamma-producing cells were induced by lower levels of stimulation than IL-4-producing cells, although optimal induction of both was seen with the same high level of stimulation. Over the long term, however, high doses of high affinity peptides led selectively to IFN-gamma-secreting cells, whereas IL-4- and IL-5-secreting cells predominated with lower levels of initial signaling, brought about by moderate doses of high affinity peptides. In contrast, too low a level of stimulation at the naive T cell stage, with low affinity peptides at any concentration, promoted only IL-2-secreting effectors or was not sufficient for long term T cell survival. These results demonstrate that the level of signaling achieved through the TCR is intimately associated with the induction of distinct cytokine-secreting T cells. We show that dose, affinity, time over which differentiation occurs, and initial production of IL-4 and IFN-gamma all can contribute to which T cell subset will predominate. Furthermore, these data reconcile the two opposing views on the effects of dose and affinity and provide a unifying model of Th1/Th2 differentiation based on strength of signaling and length of response.
Division of Immunochemistry, La Jolla Institute for Allergy and Immunology, San Diego, CA 92121, USA.
P R
PR
Rogers
M
M
Croft
D000595:Amino Acid Sequence; D000818:Animals; D000941:Antigens / Q000276:immunology / Q000378:metabolism / Q000494:pharmacology; D002454:Cell Differentiation / Q000276:immunology; D003574:Cytochrome c Group / Q000276:immunology / Q000378:metabolism / Q000494:pharmacology; D016207:Cytokines / Q000037:antagonists & inhibitors / Q000096:biosynthesis*; D004306:Dose-Response Relationship, Immunologic; D016130:Immunophenotyping; D007371:Interferon-gamma / Q000378:metabolism / Q000502:physiology; D018664:Interleukin-12 / Q000502:physiology; D007376:Interleukin-2 / Q000096:biosynthesis; D015847:Interleukin-4 / Q000378:metabolism / Q000502:physiology; D007399:Interphase / Q000276:immunology; D007424:Intracellular Fluid / Q000737:chemistry / Q000276:immunology; D008213:Lymphocyte Activation / Q000276:immunology; D051379:Mice; D008810:Mice, Inbred C57BL; D008822:Mice, Transgenic; D008969:Molecular Sequence Data; D009036:Moths; D010455:Peptides / Q000276:immunology* / Q000378:metabolism* / Q000494:pharmacology; D011485:Protein Binding / Q000276:immunology; D013194:Staining and Labeling; D018417:Th1 Cells / Q000166:cytology / Q000378:metabolism*; D018418:Th2 Cells / Q000166:cytology / Q000378:metabolism*; D013997:Time Factors
D000941:Antigens; D003574:Cytochrome c Group; D016207:Cytokines; D007376:Interleukin-2; D010455:Peptides; D018664:Interleukin-12; D015847:Interleukin-4; D007371:Interferon-gamma